PKM and neoplasm: Despite the increasingly appreciated role of shikonin in sensitizing tumor cells to cisplatin in cancers like non-small cell lung cancer [40], and bladder cancer [41], the combined administration of both shikonin and cisplatin was not evaluated in triple-negative breast cancer yet; our finding demonstrates the potential clinical utility of targeting PKM2 in triple-negative breast cancer therapy.